Course Achievements

2025年

  1. Matsuo M, Liu S, Yamada H, Takemasa E, Suzuki Y, Mogi M. Time-sensitive effects of quercetin on rat basophilic leukemia (RBL-2H3) cell responsiveness and intracellular signaling. PLoS One. 20:e0319103, 2025
  2. Miyaue N, Yamamoto H, Liu S, Ito Y, Yamanishi Y, Ando R, Suzuki Y, Mogi M, Nagai M. Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson’s disease. NPJ Parkinsons Dis. 11:49, 2025
  3. Kume T, Mogi M. The inseparable relationship between constipation and blood pressure. Hypertens Res. 48:OO-OO, 2025
  4. Mogi M, Ikegawa Y. Close relationship between systemic blood pressure and intraocular pressure. Hypertens Res. 48:882-883, 2025
  5. Mogi M, Kukida M. Factors associated with blood pressure regulation in vascular smooth muscle cells. Hypertens Res. 48:OO-OO, 2025
  6. Mogi M, Takeshita H. Analysis of modifying factors for ACE2 to work effectively. Hypertens Res. 48:OO-OO, 2025
  7. Mogi M, Hoshide S, Kario K. Participating in ISH 2024. Hypertens Res. 48:879, 2025
  8. Mogi M. Further development in the trees of the immune system is expected to elucidate the mechanisms of blood pressure elevation. Hypertens Res. 48:1214-1215, 2025
  9. Mogi M. New possibilities for protective arms by changing the structure of angiotensin (1-9). Hypertens Res. 48:880-881, 2025
  10. Mizokami F, Tomohiro Mizuno T, Taguchi R, Nasu I, Arai S, Higashi K, Matsumoto A, Kamei M, Kojima T, Sakai T, Shibata Y, Takeya Y, Mogi M, Yamada S, Akishita M. Japanese Society of Geriatric Pharmacy Working Group on Japanese Anticholinergic Risk ScaleDevelopment of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 25: 5-13, 2025
  11. Kario K, Nishiyama A, Shibata S, Arima H, Furuhashi M, Ichihara A, Ishida M, Katsuya T, Kishi T, Miura K, Miura SI, Mogi M, Ohishi M, Shibata H, Shimosawa T, Sugawara A, Tamura K, Toyoda K, Yamamoto K, Node K. Digital hypertension, implementation hypertension, and internationalization – 3 pillars of Japanese Society of Hypertension 2024-2026 advancing hypertension science from Japan to the world in the information network era. Hypertens Res. 48:1-5, 2025
  12. Kario K, Hoshide S, Mogi M. Hypertension Research global initiatives 2025 added new themes-“implementation hypertension” and “morning hypertension”. Hypertens Res. 48:877-878, 2025
  13. Karen L. Whalen (著) / 櫻井 隆 , 丸山 敬 , 柳澤 輝行 (監訳) /青山 晃治, 喜多 紗斗美, 西堀 正洋, 朝賀 鈍一, 衣笠 泰葉, 林 啓太朗, 有賀 純, 工藤 賢三, 東 洋一郎, 安西 尚彦, 栗原 順一, 平塚 真弘, 池田 康将, 呉林 なこみ, 藤田 朋恵, 池田 龍ニ, 齊藤 源顕, 船本 雅文, 石井 邦明, 坂本 謙司 堀之内 孝広, 猪爪 隆史, 櫻井 隆, 丸山 敬, 今井 由美子, 清水 孝洋, 茂木 正樹, 今村 武史, 周防 諭, 籾山 俊彦, 岩本 隆宏, 武田 泰生, 谷内 一彦, 大内 基司, 田中 秀和, 柳澤 輝行（訳者）イラストレイテッド薬理学 原書8版　2025年1月30日発行 ISBN 978-4-621-31043-4　丸善出版

2024年

  1. Imai M, Liu S, Yano A, Suzuki Y, Mogi M, Sugiyama T. Feasibility and efficacy of pemafibrate for prevention of maternal high-fat intake-induced glucose metabolic dysfunction in offspring. Biochem Pharmacol. 227:116454, 2024
  2. Watanabe R, Liu S, Sakaue T, Ikegawa Y, Ohta M, Higaki T, Mogi M, Eguchi M. Amelioration of oxygen-induced retinopathy in neonatal mice with fetal growth restriction. Front Cell Dev Biol. 12:1288212, 2024
  3. Suzuki Y, Liu S, Yamashita N, Yamaguchi N, Takasaki Y, Yorozuya T, Mogi M. Perioperative Anaphylaxis in Japanese Secondary Care Institutions: Incidence, Causes, and the Imperative for Improved Diagnostic Practices. Cureus. 16:e57555, 2024
  4. Mogi M, Tanaka A, Node K, Tomitani N, Hoshide S, Narita K, Nozato Y, Katsurada K, Maruhashi T, Higashi Y, Matsumoto C, Bokuda K, Yoshida Y, Shibata H, Toba A, Masuda T, Nagata D, Nagai M, Shinohara K, Kitada K, Kuwabara M, Kodama T, Kario K. 2023 update and perspectives. Hypertens Res. 47:6-32, 2024
  5. Mogi M, Ikegawa Y, Haga S, Hoshide S, Kario K. Hypertension facilitates age-related diseases. ~ Is hypertension associated with a wide variety of diseases?~ Hypertens Res. 47:1246-1259, 2024
  6. Mogi M, Hoshide S, Kario K. The latest topics related to hypertension are concentrated. Hypertens Res. 47:3303, 2024
  7. Mogi M. Small vessels cause big problems. Hypertens Res. 47:2930-2932, 2024
  8. Mogi M. Pulse pressure tells the story of sarcopenia. Hypertens Res. 47:2583-2585, 2024
  9. Mogi M. Effect of adrenomedullin on obesity-related hypertension. Hypertens Res. 47:2221-2222, 2024
  10. Mogi M, Hoshide S, Kario K. Hypertension in Asia: Genetic, lifestyle, and clinical insights. Hypertens Res. 47:2007-2008, 2024
  11. Mogi M, Hoshide S, Kario K. Preface-risk of hypertension to cardiovascular disease and beneficial effects of drugs. Hypertens Res. 47:2236-2237, 2024
  12. Mogi M, Hoshide S, Kario K. Consider hypertension risk factors once again. Hypertens Res. 47:1443-1444, 2024
  13. Mogi M, Hoshide S, Kario K. Preface-various factors in the management of blood pressure. Hypertens Res. 47:577-578, 2024
  14. Takeshita H, Yamamoto K, Mogi M, Rakugi H. Muscle mass, muscle strength and the renin-angiotensin system. Clin Sci (Lond). 138:1561-1577, 2024
  15. Kario K, Hoshide S, Mogi M. The need for a personalized “implementation hypertension” strategy to facilitate the implementation of the new European Society of Hypertension (2023), European Society of Cardiology (2024) and the upcoming Japanese Society of Hypertension (2025) hypertension guidelines in clinical practice. Hypertens Res. 47:3380-3382, 2024
  16. Kario K, Hoshide S, Mogi M. Renal denervation up-to-date 2024: evidence and perspectives in Japan. Hypertens Res. 47:2621-2623. 2024
  17. Kario K, Hoshide S, Mogi M. Salt and seasonal variation research in Asia. Hypertens Res. 47:833-834, 2024
  18. Kario K, Hoshide S, Mogi M. Hypertension treatment up-date on World Hypertension Day 2024: current status and future prospects in Asia. Hypertens Res. 47:1763-1765, 2024
  19. Kario K, Hoshide S, Mogi M. The Editorial Structure 2024 of Hypertension Research for global initiatives. Hypertens Res. 47:251-252, 2024
  20. Kario K, Okura A, Hoshide S, Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res. 47:1099-1102, 2024
  21. Hoshide S, Mogi M, Kario K. Asian hypertensive population: key insights from large-scale data analysis. Hypertens Res. 47:2979-2980, 2024
  22. Hoshide S, Mogi M, Kario K. Hypertension in Asia: Genetic, lifestyle, and clinical insights. Hypertens Res. 47:2007-2008, 2024
  23. Hoshide S, Mogi M, Kario K. Original article and review highlighted in this month of Hypertension Research. Hypertens Res. 47:1095-1096, 2024
  24. Hoshide S, Mogi M, Kario K. Intriguing review and topics in this month of Hypertension Research. Hypertens Res. 47:253-254. 2024
  25. Mogi M, Liu S. Institutional Review Board Considerations for Clinical Trials. Methods Mol Biol. 2766:311-316, 2024 (Book)
  26. Mogi M, Liu S. Animal Models of Vasculitis. Methods Mol Biol. 2766:271-280, 2024 (Book)
  27. Liu S. Evaluation of Autoreactive Responses. Methods Mol Biol. 2766:241-245, 2024 (Book)
  28. Liu S. Release of Antibodies and Cytokines from B Cells. Methods Mol Biol. 2766:233-240, 2024 (Book)
  29. Liu S. Electrophysiological Methods to Measure Ca2+ Current. Methods Mol Biol. 2766:191-198, 2024 (Book)
  30. Liu S. Single-Cell Ca2+ Imaging. Methods Mol Biol. 2766:183-190, 2024 (Book)
  31. Liu S. Mesenchymal Stem Cell Engineering. Methods Mol Biol. 2766:169-174, 2024 (Book)
  32. Liu S. Lentiviral Production Platform. Methods Mol Biol. 2766:163-168, 2024 (Book)
  33. Liu S. Lentiviral-Mediated Systemic RNA Interference In Vivo. Methods Mol Biol. 2766:153-161, 2024 (Book)
  34. Liu S. RNA Interference Ex Vivo. Methods Mol Biol. 2766:145-151, 2024 (Book)
  35. Liu S, Suzuki Y, Inui M. Generation of Specific Aptamers. Methods Mol Biol. 2766:129-137, 2024 (Book)
  36. Liu S, Takemasa E. Preparation of Joint Extracts. Methods Mol Biol. 2766:55-60, 2024 (Book)
  37. Liu S, Miyoshi M. Long-Term Constant Subcutaneous Drug Administration. Methods Mol Biol. 2766:31-36, 2024 (Book)
  38. Liu S. Scaffolded Chondrogenic Spheroid-Engrafted Model. Methods Mol Biol. 2766:17-24, 2024 (Book)
  39. Liu S. Human Xenograft Model. Methods Mol Biol. 2766:9-15, 2024 (Book)
  40. Suzuki Y, Liu S. Bulk RNA-seq Assessment of Murine Spleen Using a Portable MinION Sequencing Device. Methods Mol Biol. 2766:293-307, 2024 (Book)
  41. Takemasa E, Liu S. Screening of Ca2+ Influx in Lymphocytes. Methods Mol Biol. 2766:177-182, 2024 (Book)
  42. Takemasa E, Liu S. Production of Neutralizing Antibody. Methods Mol Biol. 2766:93-106, 2024 (Book)
  43. Takemasa E, Liu S. Denervation-Induced Sarcopenia Model. Methods Mol Biol. 2766:25-30, 2024 (Book)
  44. Miyoshi M, Liu S. Clinical Scoring of Disease Activity in Animal Models. Methods Mol Biol. 2766:37-42, 2024 (Book)
  45. Miyoshi M, Liu S. Collagen-Induced Arthritis Models. Methods Mol Biol. 2766:3-7, 2024 (Book)
  46. Marii M, Liu S. Evaluation of Mitochondrial Respiratory Function in Murine Splenocytes. Methods Mol Biol. 2766:199-206, 2024 (Book)
  47. 茂木正樹　ACE阻害薬が積極的に使用されるのはどのような場合？　循環器疾患　高血圧　『健康寿命を考えた日常頻用薬の選び方・使い方』　藤村昭夫／企画編集　2024年10月26日発行 ISBN 978-4787826510　診断と治療社
  48. 茂木正樹　加齢性疾患に対する多面的アプローチ（老化細胞除去薬の可能性も含めて）練馬区医師会報「だより」2024年2月号
  49. 茂木 正樹、劉 爽、鈴木 康之、山田 静雄　“抗コリン様作用”を深堀する─「日本版抗コリン薬リスクスケール」の発表を受けて改めて考える─　一般社団法人日本老年薬学会編　日本老年薬学会雑誌　2024年 7巻 4号 p.69-76.　2024年12月
  50. 秋下 雅弘、新井 さやか、亀井 美和子、小島 太郎、阪井 丘芳、柴田 ゆうか、田口 怜奈、竹屋 泰、那須 いずみ、東 敬一朗、松本 彩加、水野 智博、溝神 文博、茂木 正樹、山田 靜雄、（日本版抗コリン薬リスクスケール作成ワーキンググループ）　『日本版抗コリン薬リスクスケール』　一般社団法人日本老年薬学会編　日本老年薬学会雑誌　2024年5月17日

2023年

  1. Yano A, Liu S, Suzuki Y, Imai M, Mogi M, Sugiyama T. Single-cell transcriptomic architecture and cellular communication circuits of parametrial adipose tissue in pregnant mice. Life Sci. 334:122214, 2023
  2. Liu S, Mochizuki M, Suzuki Y, Takemasa E, Yano A, Imai M, Mogi M. Dietary leucine supplementation restores T-cell mitochondrial respiration and regulates T-lineage differentiation in denervation-induced sarcopenic mice. J Nutr Biochem. 124:109508, 2023
  3. Liu S, Takemasa E, Suzuki Y, Mogi M. Exploring an immortal Turritopsis sp. as a less conventional natural system for study of aging. Biochemistry and Biophysics Reports. 37:101613, 2023
  4. Kiyoi T, Liu S, Takemasa E, Hato N, Mogi M. Intermittent environmental exposure to hydrogen prevents skin photoaging through reduction of oxidative stress. Geriatr Gerontol Int. 23: 304-312. 2023.
  5. Takeshita H, Yamamoto K, Mogi M, Nozato S, Rakugi H. Is the anti-aging effect of ACE2 due to its role in the renin-angiotensin system?-Findings from a comparison of the aging phenotypes of ACE2-deficient, Tsukuba hypertensive, and Mas-deficient mice. Hypertens Res. 46:1–11, 2023
  6. Mogi M, Liu S, Watanabe R, Imai M, Yano A, Ikegawa Y, Kato H. Perspectives on frailty as a total life-course disease with consideration of the fetal environment. Geriatr Gerontol Int. 23：263-269, 2023.
  7. Shibata S, Kobayashi K, Tanaka M, Asayama K, Yamamoto E, Nakagami H, Hoshide S, Kishi T, Matsumoto C, Mogi M, Morimoto S, Yamamoto K, Mukoyama M, Kario K, Node K, Rakugi H. COVID-19 pandemic and hypertension: an updated report from the Japanese Society of Hypertension project team on COVID-19. Hypertens Res. 46:589-600, 2023.
  8. Matsumoto C, Shibata S, Kishi T, Morimoto S, Mogi M, Yamamoto K, Kobayashi K, Tanaka M, Asayama K, Yamamoto E, Nakagami H, Hoshide S, Mukoyama M, Kario K, Node K, Rakugi H. Long COVID and hypertension-related disorders: a report from the Japanese Society of Hypertension Project Team on COVID-19. Hypertens Res. 46:601-619, 2023
  9. Mogi M, Hoshide S, Kario K. Optimal blood pressure and improvement of achievement rate. Hypertens Res. 46:2445-2446, 2023
  10. Mogi M. Renin-angiotensin system in the placenta of women with preeclampsia. Hypertens Res. 46:2243-2244, 2023
  11. Mogi M. Manganese exposure is a risk for brain atrophy. Hypertens Res. 46:1883-1885, 2023
  12. Mogi M, Hoshide S, Kario K. Determinants and clinical implication of hypertension from childhood to old age in Asian subjects. Hypertens Res. 46:1827-1828, 2023
  13. Mogi M, Alfie J. Clues to suspect aldosterone breakthrough in the real world. Hypertens Res. 46:1819-1820, 2023
  14. Mogi M, Hoshide S, Kario K. Home blood pressure measurement: the original and the best for predicting the risk. Hypertens Res. 46:1745-1746, 2023
  15. Mogi M. Mechanical stress is involved in mechanism of hypertensive nephropathy. Hypertens Res. 46:1335-1336, 2023
  16. Mogi M, Hoshide S, Kario K. Preface-Metabolic aspects of hypertension in Asia. Hypertens Res. 46:1071-1072, 2023
  17. Mogi M. LOX prevents abdominal aortic aneurysm ruptures. Hypertens Res. 46:801-802, 2023
  18. Mogi M. Prediction of intradialytic hypotension. Hypertens Res. 46:774-775, 2023
  19. Mogi M, Hoshide S, Kario K. Preface-this month’s Asian perspectives. Hypertens Res.46:343-344, 2023
  20. Mogi M. Introduction of the 13th Hypertension Research Awards for authors of outstanding papers in Hypertension Research. Hypertens Res. 46:295-296, 2023
  21. Mogi M. Reply to comments about “Aldosterone breakthrough”. Hypertens Res. 23:263-269, 2023.
  22. Kario K, Hoshide S, Mogi M. Five special focuses of Hypertension Research: digital hypertension, home blood pressure-centered approach, renal denervation, Asians, for guidelines. Hypertens Res. 46:2557-25601, 2023
  23. Kario K, Hoshide S, Mogi M, Nishiyama A, Ohya Y, Node K. What impacts do the new ESH 2023 guidelines have on the management of hypertension in Japan? Hypertens Res. 46:2257-2261, 2023
  24. Kario K, Hoshide S, Mogi M. The new editorial board 2023 of Hypertension Research for global initiatives. Hypertens Res. 46:1624-1635, 2023
  25. Kario K, Hoshide S, Mogi M. Topics 2023 in Hypertension Research leading to guidelines in Asia. Hypertens Res. 46:1357-1362, 2023
  26. Kario K, Hoshide S, Mogi M. Lifetime home BP-centered approach is the core from onset to aggravation of hypertension. Hypertens Res. 46:553-555, 2023
  27. Hoshide S, Mogi M, Kario K. How do we tackle nighttime blood pressure? Hypertens Res. 46:2262-2263, 2023
  28. Hoshide S, Mogi M, Kario K. Sympathetic nervous activation and hypertension. Hypertens Res. 46:1636-1637, 2023
  29. Hoshide S, Mogi M, Kario K. The importance of lifestyle modification for hypertension in Asia. Hypertens Res. 46:815-816, 2023
  30. Hoshide S, Mogi M, Kario K. Target organ damage for the management of hypertension in the Asian population. Hypertens Res. 46:297-298, 2023
  31. Liu S, Mogi M. Impact of Cancer-Related Sarcopenia on Systemic Immune Status. Cancer Research: An Interdisciplinary Approach, Springer, eBook ISBN 978-3-031-32458-1, 567-588, 2023 (Book)
  32. 茂木正樹　薬の基本とはたらきがわかる薬理学（教科書）　第10章　循環器系疾患治療薬　柳田俊彦／編　2023年10月30日発行 B5判 349ページ ISBN 978-4-7581-2169-9　羊土社
  33. 茂木正樹　高齢者の降圧治療と認知症「日本老年薬学会雑誌」6巻　1号　1-7頁　2023年
  34. 茂木正樹　6. 認知症（SPRINT研究を基にした考察）高血圧の最新診断・治療update ―診断・治療の最新動向―　Ⅳ. 合併症・ライフステージと高血圧診療「日本臨牀」81巻　1号　114-120頁　2023年
  35. 茂木正樹　高血圧の専門家愛媛大学大学院教授茂木正樹先生に聞いた高血圧予防＆血圧をラク～に下げる方法　大人の脳活ドリル&血圧をラク～に下げるいきいき生活60日―高血圧は、認知症につながる要因の1つだった!　主婦と生活社　2023年12月15日発売

2022年

  1. Ueno M, Liu S, Kiyoi T, Mogi M, Sugiyama T. Long-term impact of maternal dietary intervention on metabolic homeostasis in male offspring in mice. J Nutr Biochem. 20;108971, 2022
  2. Ueno M, Liu S, Kiyoi T, Sugiyama T, Mogi M. Perinatal low-fat dietary intervention affects glucose metabolism in female adult and aging offspring. Geriatr Gerontol Int. 22:441-448, 2022
  3. Liu S, Suzuki Y, Yorozuya T, Mogi M. Machine-learning-based analytics for risk forecasting of anaphylaxis during general anesthesia. Immuno-informatics. 8: 100018, 2022
  4. Liu S, Takemasa E, Suzuki Y, Javkhlant A, Takagi T, Yamada H, Hato N, Mogi M. Generation of DNA-aptamers targeting galectin-7 for the identification of cholesteatoma residue. J Pharmacol Sci. 150:146-153, 2022
  5. Liu S, Suzuki Y, Takemasa E, Watanabe R, Mogi M. Mast cells promote viral entry of SARS-CoV-2 via formation of chymase/spike protein complex. Eur J Pharmacol. 930:175169, 2022
  6. Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M, Bokuda K, Ichihara A, Nozato Y Toba A, Narita K, Hoshide S, Tanaka A, Node K, Yoshida Y, Shibata H, Katsurada K, Kuwabara M, Kodama T, Shinohara K, Kario K. Update on Hypertension Research in 2021. Hypertens Res. 45:1276-1297, 2022
  7. Mogi M, Higashi Y, Bokuda K, Ichihara A, Nagata D, Tanaka A, Node K, Nozato Y, Yamamoto K, Sugimoto K, Shibata H, Hoshide S, Nishizawa H, Kario K. Annual reports on hypertension research 2020. Hypertens Res. 45: 15-31, 2022
  8. Mogi M. Effect of estrogen on fetal programming in offspring from high-fat-fed mothers. Hypertens Res. 45:1835-1837. 2022
  9. Mogi M, Hoshide S, Kario K. The eighth installment in Asian perspectives, salt, pregnancy, and masked hypertension. Hypertens Res. 45:1677-1678, 2022.
  10. Mogi M, Hoshide S, Kario K. The fifth story in Asian perspectives, regions, new markers, and renal denervation. Hypertens Res. 45:1223-1224. 2022
  11. Mogi M. Aldosterone breakthrough from pharmacological perspective. Hypertens Res. 45: 967–975, 2022
  12. Mogi M. Is COVID-19 vaccination beneficial or harmful to endothelial cells? Hypertens Res. 45: 920-921. 2022.
  13. Mogi M. Hypertension management to prevent dementia. Hypertens Res. 45:573-575. 2022
  14. Mogi M, Hoshide S, Kario K. Latest hypertension research to inform clinical practice in Asia. Hypertens Res. 45:555-572. 2022
  15. Mogi M. Is renal denervation a natural antihypertensive treatment? Hypertens Res. 46:289-290, 2022
  16. Mogi M. Clinical study on angiotensin II vaccination-the first big step. Hypertens Res. 45: 162-163, 2022.
  17. Higaki A, Mogi M. Dendritic cells as potential initiators of immune-mediated hypertensive disorders. Hypertens Res. 45:527-529. 2022.
  18. Kario K, Hoshide S, Mogi M. A recent advance in Renal denervation to clinical practice. Hypertens Res. 45:1906-1907, 2022
  19. Kario K, Hoshide S, Mogi M. Uncontrolled hypertension: the greatest challenge and perspectives in Asia. Hypertens Res. 45:1847-1849, 2022
  20. Kario K, Hoshide S, Mogi M. Digital Hypertension 2023: Concept, hypothesis, and new technology. Hypertens Res. 45:1529-1530
  21. Kario K, Mogi M, Hoshide S. Effect of COVID-19 pandemic on seasonal cardiovascular mortality in Japan, and Asian evidence. Hypertens Res. 45:1405-1407. 2022
  22. Kario K, Mogi M, Hoshide S. Preface–special issue on hypertension in Asia: the second story. Hypertens Res. 45:747. 2022
  23. Kario K, Mogi M, Hoshide S. Latest hypertension research to inform clinical practice in Asia. Hypertens Res. 45:555-572. 2022
  24. Kario K, Mogi M, Hoshide S. New Editorial Hypertension Research: Looking back to 2021 and perspective to 2022. Hypertens Res. 45: 181-185, 2022.
  25. Hoshide S, Mogi M, Kario K. The next stage of hypertension management in Asia. Hypertens Res. 45:1552, 2022
  26. Hoshide S, Mogi M, Kario K. Current status of hypertension and treatment in Asia. Hypertens Res. 45:1095-1096. 2022
  27. Hoshide S, Nishiyama A, Mogi M, Kario K. Preface-Special issue for hypertension in Asia: from the Okinawa declaration to the ISH 2022. Hypertens Res. 45:553-554. 2022

2021年

  1. Suzuki Y, Liu S, Kadoya F, Takasaki Y, Yorozuya T, Mogi M. Association between mutated Mas-related G-protein-coupled receptor-X2 and rocuronium-induced intraoperative anaphylaxis. Comment on Br J Anaesth 2020; 125: e448-50. Br J Anaesth. 127:e21-e22, 2021.
  2. Sahid MNA, Liu S, Kiyoi S, Maeyama K, Mogi M. Inhibition of histamine release from RBL-2H3 cells by zoledronate did not affect Rab27a/Doc2a interaction: Hint for exocytosis-protein prenylation hierarchy. Biol. Pharm. Bull. 44, 1902–1906, 2021
  3. Hanayama M, Yamamoto Y, Utsunomiya H, Yoshida O, Liu S, Mogi M, Matsuura B, Takeshita E, Ikeda Y, Hiasa Y. The mechanism of increased intestinal palmitic acid absorption and its impact on hepatic stellate cell activation in nonalcoholic steatohepatitis. Sci Rep. 11:13380.2021.
  4. Takeshita H, Yamamoto K, Mogi M, Wang Y, Nozato Y, Fujimoto T, Yokoyama S, Hongyo K, Nakagami F, Akasaka H, Takami Y, Takeya Y, Sugimoto K, Horiuchi M, Rakugi H. Double Deletion of Angiotensin II Type 2 and Mas Receptors Accelerates Aging‐Related Muscle Weakness in Male Mice. J Am Heart Assoc. 10:e021030, 2021
  5. Bai HY, Min LJ, Shan BS, Iwanami J, Kan-No H, Kanagawa M, Mogi M, Horiuchi M. Angiotensin II and Amyloid-β Synergistically Induce Brain Vascular Smooth Muscle Cell Senescence. Am J Hypertens. 34:552-562, 2021.
  6. Mogi M. Cardioprotection by direct factor Xa inhibition in angiotensin II overexpression. Hypertens Res. 44:1355-1356, 2021
  7. Mogi M. A disturbance beyond the barrier-chronic kidney disease allows angiotensinogen invasion. Hypertens Res. 44:874-876. 2021.
  8. 茂木 正樹，古屋敷 智之，田熊 一敞，乙黒 兼一，田中 智之，南 雅文「COVID-19 に対する各大学の対応と生理学及び薬理学教育への影響に関する緊急合同調査」についての結果報告　特集：With/after コロナ時代の新たな薬理学教育Ⅰ：遠隔教育の実践と課題　「日本薬理学会雑誌」156巻　324～329頁　2021年

2020年

  1. Liu S, Kiyoi T, Takemasa E, Mogi M. Denervation‐induced loss of skeletal muscle mass influences immune homeostasis and accelerates the disease progression of lupus nephritis. JCSM Clin Rep. 5: 108-120, 2020
  2. Liu S, Kiyoi T, Ishida M, Mogi M. Assessment and comparison of the efficacy of methotrexate, prednisolone, adalimumab, and tocilizumab on multipotency of mesenchymal stem cells. Front Pharmacol. 11: 1004, 2020
  3. Suzuki Y, Liu S, Kadoya F, Takasaki Y, Yorozuya T, Mogi M. Association between mutated Mas-related G protein-coupledreceptor-X2 and rocuronium-induced intraoperative anaphylaxis. Br J Aneasth. 125: e446-e448. 2020
  4. Suzuki Y, Liu S, Ogasawara T, Sawasaki T, Takasaki Y, Yorozuya T, Mogi M. A Novel MRGPRX2-targeting Antagonistic DNA Aptamer Inhibits Histamine Release and Prevents Mast Cell-Mediated Anaphylaxis. Eur J Pharmacol. 878: 173104, 2020
  5. Kiyoi T, Liu S, Takemasa E, Nakaoka H, Hato N, Mogi M. Constitutive hydrogen inhalation prevents vascular remodeling via reduction of oxidative stress. PLoS One 15: e0227582, 2020
  6. Sahid MNA, Liu S, Mogi M, Maeyama K. Tachykinin-1 receptor antagonism suppresses substance-P- and compound 48/80-induced mast cell activation from rat mast cells expressing functional mas-related GPCR B3. Inflamm Res. 69; 289-298, 2020
  7. Takeshita H, Yamamoto K, Mogi M, Nozato S, Horiuchi M, Rakugi H. Different effects of the deletion of angiotensin converting enzyme 2 and chronic activation of the renin-angiotensin system on muscle weakness in middle-aged mice. Hypertens Res. 43:296-304, 2020
  8. Nozato S, Yamamoto K, Takeshita H, Nozato Y, Imaizumi Y, Fujimoto T, Yokoyama S, Nagasawa M, Takeda M, Hongyo K, Akasaka H, Takami Y, Takeya Y, Sugimoto K, Mogi M, Horiuchi M, Rakugi H. Angiotensin 1-7 alleviates aging-associated muscle weakness and bone loss, but is not associated with accelerated aging in ACE2-knockout mice. Clin Sci (Lond). 133:2005-2018, 2019
  9. Min LJ, Iwanami J, Shudo M, Bai HY, Shan BS, Higaki A, Mogi M, Horiuchi M. Deterioration of Cognitive Function after Transient Cerebral Ischemia with Amyloid-β Infusion. ~Possible Amelioration of Cognitive Function by AT2 Receptor Activation~. J Neuroinflammation. 17: 106, 2020
  10. Yamaguchi A, Jitsuishi T, Hozumi T, Iwanami J, Kitajo K, Yamaguchi H, Mori Y, Mogi M, Sawai S. Temporal Expression Profiling of DAMPs-related Genes Revealed the Biphasic Post-Ischemic Inflammation in the Experimental Stroke Model. Mol Brain. 13:57, 2020
  11. Yamamoto M, Yanagisaw R, Sakai A, Mogi M, Shuto S, Shudo M, Kashiwagi H, Kudo M, Nakamura M, Sakamoto M. Toxicokinetics of methylmercury in diabetic KK-Ay mice and C57BL/6 mice. J Appl Toxicol. 41;928-940, 2021
  12. Mogi M. Effect of renin–angiotensin system on senescence. Geriatr Gerontol Int. 20: 520-525, 2020
  13. Mogi M. Could Management of Blood Pressure Prevent Dementia in the elderly? Clin Hypertens. 25:27, 2019
  14. Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, Kario K, Kishi T, Mogi M, Nishiyama A, Ohishi M, Ohkubo T, Tamura K, Tanaka M, Yamamoto E, Yamamoto K, Itoh H. Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 43: 1028-1046, 2020
  15. Mogi M. Reply to comments on “Is Sarcopenia Primarily Age- or Renin Angiotensin System-Related Disorder? Geriatr Gerontol Int 20: 1000, 2020
  16. 茂木 正樹，松下 涼子　医学部薬理学関連講座における講義・実習に関する全国実態調査の結果から　連載：これからの薬理学教育を考える「日本薬理学会雑誌」155巻　47-50頁　2020年
  17. 茂木正樹　組織RA系（脳内RA系を含む）「高血圧　上　-高血圧制圧の現状と展望-」V. レニン-アンジオテンシン-アルドステロン系（RAA系）研究の現状と展望　「日本臨床」78巻　増刊号１　263-268頁　2020年　
  18. 茂木正樹　基礎研究のトピックス　これからの新規降圧薬開発　【高血圧診療update-診断・治療の最新動向-】　「日本臨床」78巻　2号　2020年

2019年

  1. Kiyoi T, Liu S, Sahid MNA, Shudou M, Ogasawara M, Mogi M, Maeyama K. Morphological and functional analysis of beige (Chèdiak-Higashi syndrome) mouse mast cells with giant granules. Int Immunopharmacol. 69:202-212, 2019
  2. Slamet Soetanto T, Liu S, Sahid MNA, Maeyama K, Mogi M. Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol. 849: 75-83, 2019
  3. Liu S, Minae M, Kiyoi T, Mogi M. Genetic Manipulation of Calcium Release-Activated Calcium Channel 1 Modulates the Multipotency of Human Cartilage-Derived Mesenchymal Stem Cells. J Immunol Res. 2019:7510214, 2019
  4. Magomed M, Singh RB, Mogi M, Lee MCI, Chibiso S, Bawareed AO, Khabirov A, Alsmadi YM, Watanabe S, Komatsu T, Agarwal N. Eating Behavior and Risk of Cardio-Metabolic Diseases. World Heart Journal, 11; 141-148, 2019 22. Singh RB, Torshi VI, Chibisov S, Goyal RK, Watanabe S, Nakagami H, Mogi M, Nayak BN. Can Protective Factors Inculcate Molecular Adaptations of Cardiomyocyte in the Prevention of Chronic Heart Failure? World Heart Journal, 11; 149-157, 2019
  5. 茂木正樹　サルコペニア肥満に対する異所性脂肪沈着制御に着目した新規治療法の探索　「日本老年医学会雑誌」　56巻　350-352頁　2019年

2018年

  1. Suzuki Y, Ogasawara T, Tanaka Y, Takeda H, Sawasaki T, Mogi M, Liu S, Maeyama K. Functional G-Protein-Coupled Receptor (GPCR) Synthesis: The Pharmacological Analysis of Human Histamine H1 Receptor (HRH1) Synthesized by a Wheat Germ Cell-Free Protein Synthesis System Combined with Asolectin Glycerosomes. Front Pharmacol. 9: 38, 2018
  2. Yamauchi T, Mogi M, Kan-no H, Shan BS, Higaki A, Min LJ, Higaki T, Iwanami J, Ishii E, Horiuchi M. Roles of Angiotensin II Type 2 Receptor in Mice with Fetal Growth Restriction. Hypertens Res. 41: 157-164, 2018
  3. Mogi M, Kohara K, Tabara Y, Tsukuda K, Igase M, Horiuchi M. Correlation between 24-Hour Urinary Angiotensinogen or Aldosterone Level and Muscle Mass: Japan Shimanami Health Promoting Program Study. Hypertens Res. 41: 326-333, 2018
  4. Wang JG, Kario K, Chen CH, Park JB, Hoshide S, Huo Y, Lee HY, Li Y, Mogi M, Munakata M, Park S, Zhu D. Management of morning hypertension: a consensus statement of an Asian expert panel. J Clin Hypertens (Greenwich). 20:39-44, 2018
  5. Higaki A, Mogi M, Iwanami J, Min LJ, Bai HY, Shan BS, Kukida M, Yamauchi T, Tsukuda K, Kan-no H, Ikeda S, Higaki J, Horiuchi M. Beneficial Effect of Mas Receptor Deficiency on Vascular Cognitive Impairment in the Presence of Angiotensin II Type 2 Receptor. J Am Heart Assoc. 7: pii: e008121, 2018
  6. Higaki A, Mogi M, Iwanami J, Min LJ, Bai HY, Shan BS, Kukida M, Tsukuda K, Kan-no H, Ikeda S, Higaki J Horiuchi M. Predicting Outcome of Morris Water Maze Test in Vascular Dementia Mouse Model with Deep Learning. Plos One 13: e0191708, 2018
  7. Miyoshi M, Morizane A, Takemasa E, Suzuki Y, Kiyoi T, Liu S, Mogi M. Efficacy of Constant Long-term Delivery of YM-58483 for the Treatment of Rheumatoid Arthritis. Euro J Pharmacol 824: 89-98, 2018
  8. Mogi M, Iwanami J, Wang XL, Tsukuda K, Kan-no H, Bai HY, Shan BS, Higaki A, Min LJ, Horiuchi M. Deletion of Interferon Regulatory Factor-1 Results in Cognitive Impairment. Hypertens Res. 41: 809-816, 2018
  9. Higaki A, Mogi M, Iwanami J, Min LJ, Bai HY, Shan BS, Kukida M, Kan-no H, Ikeda S, Higaki J, Horiuchi M Recognition of Early Stage Thigmotaxis in Morris Water Maze Test with Convolutional Neural Network. Plos One 13: e0197003, 2018
  10. Liu S, Sahid MNA, Takemasa E, Maeyama K, Mogi M. Zoledronate modulates intracellular vesicle trafficking in mast cells via disturbing the interaction of myosinVa/Rab3a and sytaxin4/VAMP7. Biochem Pharmacol. 151: 18-25, 2018
  11. Kiyoi T, Liu S, Sahid MNA, Shudo M, Maeyama K, Mogi M. High-throughput screening system for dynamic monitoring of exocytotic vesicle trafficking in mast cells. Plos One 13:e0198785, 2018
  12. Mogi M, Liu S. Animal Models of Vasculitis. Methods Mol Biol. 1868:223-232, 2018 (Book)
  13. 茂木正樹、川上萌、岩波純、堀内正嗣　血管障害誘導性認知機能低下モデルにおける伊予柑ジュース飲用による認知機能低下の予防効果 「日本臨床栄養学会雑誌　総説　40巻　20-25頁　2018年
  14. 茂木正樹　【RA系阻害薬の『臓器保護作用』を再検証する】認知症の発症・進展予防にRA系阻害薬のBeyond BP lowering effectは存在するのか?　「血圧」25巻　762-766頁　2018年
  15. 茂木正樹　牛乳・乳製品と認知機能　「CLINICAL CALCIUM」：2018年4月号　医薬ジャーナル
  16. 茂木正樹　3.認知症、特集「高血圧最新診断・治療-ガイドラインから個別予見医療へ-」テーマ：III．加齢疾患の1次・2次予防　「日本臨床」76巻　1361-1366頁　2018年
  17. 茂木正樹　サルコペニア肥満　「腎・高血圧の最新治療」7巻　149頁　2018年
  18. 茂木正樹　認知症への高血圧・血管性因子の影響とレニン・アンジオテンシン系　「血管」　41巻　1⁻12頁　2018年

2017年

  1. Nakaoka H, Mogi M, Kan-no H, Tsukuda T, Bai HY, Shan BS, Kukida M, Yamauchi T, Higaki A, Horiuchi M. Effect of Olmesartan on Glucose Metabolism Involving Angiotensin Converting Enzyme 2. Immun, Endoc & Metab Agents in Med Chem. 17:2, 2017
  2. 茂木正樹「クエン酸」の疲労軽減効果　抗加齢協会　「機能性表示食品 DATA BOOK」
  3. 茂木正樹　ミカン果汁を飲むだけで動脈硬化が優位に抑制されると愛媛大の医学生の研究で判明「安心」2017年12月号